Journal of Leukocyte Biology · 2006 · 10 citations · 57 references
Life SciencesImmunologyCell SignalingImmunoregulationSignal TransductionCalcineurin InhibitorsCytokine BiologyCytokine RegulationT Cell ActivationT Cell BiologyT Cell Receptor SignalingBiologic ImmunosuppressantsCalcineurin Inhibitor ImmunosuppressionCd28 SignalingInterferon Gamma ProductionInterferon-gamma ResponsesNfat ActivationSuppressionTacrolimus Therapy
Calcineurin antagonists are known as potent immunosuppressants working particularly on T cells by virtue of their capacity to block nuclear factor of activated T cell (NFAT) activation and translocation to the nucleus. In addition to interleukin (IL)-2 suppression, T helper cell type 1 (Th1) as well as Th2 cytokine transcription is blocked by calcineurin antagonists. Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells. This increased IFN-gamma production is dependent on T cell receptor (TCR) and CD28 signaling as well as on the presence of IL-12. IL-27, which could mimic the effect of IL-12, was however less potent in inducing IFN-gamma production in the presence of CsA and TCR stimulation. Other cytokines such as IL-23, IL-18, IL-2, or the Th2-related cytokine IL-4 are not able to support a calcineurin antagonist-dependent up-regulation of IFN-gamma. CsA-dependent IFN-gamma production is observable in therapeutic concentrations. The effect is independent of IL-10 or IL-4, as addition of these cytokines could not inhibit the CsA-induced IFN-gamma production. The effect of calcineurin antagonists is associated with an increased c-fos expression and DNA-binding activity of the transcription factor activated protein-1 but not with increased DNA-binding activity of T-bet. Our study further supports the relevance of known calcineurin activities other than NFAT activation. The presented data may help to explain why concomitant infections (resulting in increased IL-12 expression) under therapy with calcineurin antagonists often have a negative impact on the activity of the underlying disease (e.g., autoimmune disease).
57
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Susanne J. Szabo, Sean Kim, Gina L. Costa et al. · Cell · 2000 · 3.5K citations · Full text
Susan Chan, B Perussia, Jean Gupta et al. · The Journal of Experimental Medicine · 1991 · 986 citations · Full text